Physician profile
Muhammad Sameed
NPI 1831612886
$7,627.31
in general payments reported to CMS, 2019-2025
7 companies · $6,509 in 2025
The $6,509 reported for 2025 was more than what 90% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.51 · 2024: $1,106 · 2025: $6,509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,100 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Travel and Lodging: $920 · Food and Beverage: $580 · Education: $14.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,100.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Travel and Lodging | $919.77 |
| Food and Beverage | $580.33 |
| Education | $14.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $6,344.26 | 2025 | Tyvaso, Tyvaso |
| Eko Health, INC. | $1,000.00 | 2024 | |
| Tactile Systems Technology INC | $149.71 | 2024-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Ani Pharmaceuticals, INC. | $49.35 | 2025 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.94 | 2024 | Ofev |
| Mallinckrodt Hospital Products INC. | $24.54 | 2024 | Acthar |
| Merck Sharp & Dohme LLC | $12.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Sameed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.